studies on retatrutide Eli Lilly's Phase 3 clinical investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments retatrutide clinical studies retatrutide Umbrella

On top of that, everyday factors like stress and poor sleep can further complicate weight loss

GLP-1 RA Strategic Approaches for Industry 31

GLP-1 receptor agonists should be avoided in pregnancy and discontinued at least 2 months before planned conception, whilst metformin is commonly used during pregnancy

An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation

Retatrutide (research code LY-3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly as a novel triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIP-R), and glucagon receptor (GCG-R)